

A nutrigenetic update on CETP gene - diet interactions on lipid-related outcomes

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open access

Wuni, R., Kuhnle, G. G. C. ORCID: <https://orcid.org/0000-0002-8081-8931>, Azzari Wynn-Jones, A. and Vimalaswaran, K. S. ORCID: <https://orcid.org/0000-0002-8485-8930> (2022) A nutrigenetic update on CETP gene - diet interactions on lipid-related outcomes. *Current Atherosclerosis Reports*, 24. pp. 119-132. ISSN 1534-6242 doi: <https://doi.org/10.1007/s11883-022-00987-y> Available at <https://centaur.reading.ac.uk/101100/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1007/s11883-022-00987-y>

Publisher: Springer

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online



A Nutrigenetic Update on *CETP* Gene–Diet Interactions on Lipid-Related Outcomes

Ramatu Wuni¹ · Gunter G. C. Kuhnle¹ · Alexandra Azzari Wynn-Jones¹ · Karani Santhanakrishnan Vimalleswaran^{1,2}

Accepted: 30 October 2021 / Published online: 31 January 2022
© The Author(s) 2022

Abstract

Purpose of Review An abnormal lipid profile is considered a main risk factor for cardiovascular diseases and evidence suggests that single nucleotide polymorphisms (SNPs) in the cholesteryl ester transfer protein (*CETP*) gene contribute to variations in lipid levels in response to dietary intake. The objective of this review was to identify and discuss nutrigenetic studies assessing the interactions between *CETP* SNPs and dietary factors on blood lipids.

Recent Findings Relevant articles were obtained through a literature search of PubMed and Google Scholar through to July 2021. An article was included if it examined an interaction between *CETP* SNPs and dietary factors on blood lipids. From 49 eligible nutrigenetic studies, 27 studies reported significant interactions between 8 *CETP* SNPs and 17 dietary factors on blood lipids in 18 ethnicities. The discrepancies in the study findings could be attributed to genetic heterogeneity, and differences in sample size, study design, lifestyle and measurement of dietary intake. The most extensively studied ethnicities were those of Caucasian populations and majority of the studies reported an interaction with dietary fat intake. The rs708272 (TaqIB) was the most widely studied *CETP* SNP, where ‘B1’ allele was associated with higher *CETP* activity, resulting in lower high-density lipoprotein cholesterol and higher serum triglycerides under the influence of high dietary fat intake.

Summary Overall, the findings suggest that *CETP* SNPs might alter blood lipid profiles by modifying responses to diet, but further large studies in multiple ethnic groups are warranted to identify individuals at risk of adverse lipid response to diet.

Keywords Cholesteryl ester transfer protein · Polymorphisms · Diet · Lipids · Genetic Epidemiology

Background

The global burden of cardiovascular diseases (CVDs) is well recognised and ischaemic heart disease alone accounted for 9 million deaths in 2019, making it the top cause of death in all parts of the world [1]. An abnormal lipid profile (dyslipidaemia), indicated by low concentrations of high-density lipoprotein cholesterol (HDL) and elevated levels of low-density lipoprotein cholesterol (LDL) or triglycerides (TG), is considered a major risk factor for CVDs [2, 3]. The cardioprotective role of HDL is thought to be dependent on the function of HDL rather than the levels of HDL, which

is reflected in individuals with scavenger receptor class B member 1 (*SCARB1*) gene mutations who have higher levels of HDL but higher CVD risk [4]. There is evidence to suggest that a combination of genetic susceptibility and environmental factors including diet is responsible for CVDs [5••, 6, 7]. Single nucleotide polymorphisms (SNPs) in lipid-related genes such as the cholesteryl ester transfer protein (*CETP*), lipoprotein lipase (*LPL*) and apolipoprotein E (*ApoE*) genes have been found to contribute to changes in lipid profiles in response to diet [8, 9, 10•]. Of these three genes, *CETP* has been shown to have more associations with blood lipids (Supplemental Table 1). *CETP* regulates the concentration and particle size of HDL cholesterol in the plasma (Fig. 1) and is considered to play an important role in reverse cholesterol transport which is a protective mechanism against atherosclerosis [11]. Increased *CETP* activity has been shown to result in lower HDL levels and is linked to higher risk of CVDs [12].

Several studies have demonstrated *CETP*–diet interactions on blood lipids; however, the findings have been

✉ Karani Santhanakrishnan Vimalleswaran
v.karani@reading.ac.uk

¹ Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, Reading RG6 6DZ, UK

² The Institute for Food, Nutrition, and Health (IFNH), University of Reading, Reading, UK




Fig. 1 The role of cholesteryl ester transfer protein in lipid metabolism

inconsistent [10•, 13–17]. The objective of this review was therefore to identify and discuss studies assessing the interactions between *CETP* SNPs and dietary factors on blood lipids and to identify the factors that can be attributed to these discrepancies.

Cholesteryl ester transfer protein (*CETP*) is a plasma glycoprotein which is secreted by the liver and is responsible for transporting cholesteryl esters and triglycerides between HDL and apolipoprotein B-containing lipoproteins such as very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) [18]. HDL is formed from lipid-free apolipoprotein A1 (ApoA1) in a process involving the removal of free cholesterol from peripheral tissues and the subsequent esterification of some of the free cholesterol into cholesteryl esters via the actions of adenosine triphosphate binding cassette transporter A1 and lecithin:cholesterol acyltransferase (LCAT) [11]. The enrichment of HDL with triglycerides makes it a substrate for hepatic lipase (HL) which then hydrolyses the triglycerides, resulting in dissociation of the lipid-free ApoA1 and a decrease in size of the HDL particle, forming small-dense HDL [18].

Materials and Methods

Selection of the Candidate Gene for the Review

To identify candidate genes which have been reported by genome-wide association (GWA) studies to influence blood lipid levels, a literature search was undertaken in December 2020, using the following keywords: (genome-wide association study OR genome-wide association scan OR genome-wide association analysis OR GWAS OR GWA) AND (Lipids OR HDL OR LDL OR VLDL OR total cholesterol OR triglycerides OR triacylglycerol OR blood lipids). The results showed that, out of 32 identified studies (Supplemental Table 1), 20 GWA studies reported statistically significant associations between *CETP* and lipids [19–38], while *LPL* was reported by 18 GWA studies [19, 20, 22, 24, 25, 28,

29, 31–41] and *APOE* was reported by 10 GWA studies [22, 24, 25, 27, 29, 30, 32, 33, 34, 37]. *CETP* was then chosen for the review as it had the highest number of hits compared to *LPL* and *APOE*.


Study identification

To identify published articles, a literature search was undertaken using PubMed (<https://pubmed.ncbi.nlm.nih.gov/>) and Google Scholar (<https://scholar.google.com/>). The search covered the earliest date of indexing through to July 2021. For PubMed, the following key terms were used: (*CETP* OR cholesteryl ester transfer protein) AND (polymorphism OR gene OR SNP OR single nucleotide polymorphism OR genetic variation OR genetic variant OR rs3764261 OR rs1532624 OR rs1800775 OR rs9989419 OR rs4783961 OR rs708272 OR rs7499892 OR rs2303790 OR rs16965220 OR rs247616 OR rs289708 OR rs12708980 OR rs247617 OR rs173539) AND ('gene-diet interaction' OR 'diet-gene interaction' OR 'SNP-diet interaction' OR 'diet-SNP interaction' OR 'gene-nutrient interaction' OR 'nutrient-gene interaction') AND (carbohydrate OR protein OR fat OR fibre OR sugar OR SFA OR MUFA OR PUFA OR Mediterranean diet OR Nordic diet OR B12 OR amino acids OR polyphenols OR egg intake OR caffeine intake OR green tea OR alcohol intake OR meat intake) AND (lipids OR HDL OR LDL OR VLDL OR total cholesterol OR triglycerides OR triacylglycerol OR blood lipids OR serum lipids). The key terms for Google Scholar were (*CETP* AND 'gene-diet interaction' AND lipids). Only studies published in English were included.

Study Selection

The search strategies above yielded a total of 448 articles from the two databases (227 from PubMed and 221 from Google Scholar) as shown in Fig. 2. Titles of all the studies were first read to determine their relevance to the topic. Full-text of those found to be relevant were then read in detail to determine eligibility for inclusion. The criteria for inclusion in the review were as follows: gene–diet interaction studies involving *CETP* gene polymorphisms and blood lipids. Only studies conducted in humans were included and, after applying the inclusion and exclusion criteria, 49 articles were found to be eligible, of which one article was published as an abstract. The studies excluded after reading the full-text were those focusing on interaction between *CETP* and physical activity on lipids; gene–diet interaction on lipids not including *CETP*; and gene–diet interaction review articles. Full-text of 48 eligible studies was read in detail and the results were extracted for analysis (Supplemental Tables 2 and 3). The results of one study [42] which was published as an abstract were also extracted and included in

Fig. 2 Flowchart of studies identified in the literature for *CETP*–diet interaction on lipids



the tables. The studies consisted of 28 observational studies (Supplemental Table 2) and 21 interventional studies (Supplemental Table 3).

Data Extraction

The studies were identified by a single investigator and the following data were double-extracted independently by one reviewer: first author, publication year, location or ethnicity of participants, sample size, mean age, study design, reference SNP (rs) ID, genotype and minor allele. Corresponding authors were contacted to provide additional information where needed.

Results of Database Search

This section reviews studies examining the interaction between dietary factors and *CETP* SNPs on blood lipids. The rs708272 (TaqIB), the most widely studied *CETP* SNP, was investigated by 31 studies. The second most studied SNP was rs5882 (I405V), accounting for 16 studies. The *CETP* SNPs rs3764261 and rs1800775 were each examined by 6 studies. All the studies were conducted in adults except for one study which was carried out in prepubertal children [43]. The ethnicities covered by the studies included British, White American, Spanish, Mexican, Chinese and Iranian as shown in Fig. 3. A wide range of dietary factors were investigated by the 28 observational studies, and these included dietary carbohydrate, protein, saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), coffee, sucrose, total energy intake and alcohol consumption. The 21 dietary intervention studies also focused on a variety of diets including Mediterranean diet, plant sterol ester, sesame oil, canola oil and rapeseed oil.

TaqIB (SNP rs708272 G > A)

The major allele ('G') is also called the 'B1' allele while the minor allele ('A') is also referred to as the 'B2' allele. Eight out of seventeen observational studies reported a significant association between TaqIB genotypes, dietary factors and blood lipids. In a cross-sectional study involving 129 Iranian patients with type 2 diabetes (T2D) without dyslipidaemia [15], a higher intake of total fat (>34.9% from total energy intake) was associated with higher HDL in participants with 'B1B1' genotype (mean HDL (mg/dl) for high total fat intake (>34.9% from total energy) vs low total fat intake (\leq 34.9% from total energy) = 58.6 ± 4.1 vs 36.5 ± 6.5 ; $P_{\text{interaction}} = 0.02$). Those with 'B2B2' genotype who had a higher intake of total fat (>34.9% from total energy) also had higher HDL (mean HDL (mg/dl) for high total fat intake (>34.9% from total energy) vs low total fat intake (\leq 34.9% from total energy) = 59.0 ± 4.2 vs 55.8 ± 3.3) but the interaction was more pronounced in individuals with 'B1B1' genotype, while in those with 'B1B2' genotype, the interaction was not observed. A prospective cohort study of 603 men with T2D in the USA (96% of whom were white) [13] on the other hand reported that a higher intake of total fat (>33.5% from total energy intake), animal fat (>19.9% from total energy intake), SFA (>11.47% from total energy intake) and MUFA (>12.75% from total energy intake) was associated with lower HDL in participants with 'B1B1' genotype compared to those with 'B2B2' genotype (mean HDL (mg/dl) for low total fat intake (\leq 33.5% of energy) vs high total fat intake (>33.5% of energy): 40.0 ± 0.03 vs 36.2 ± 0.02 for 'B1B1', 41.5 ± 0.03 vs 44.9 ± 0.03 for 'B2B2', $P_{\text{interaction}} = 0.003$; mean HDL (mg/dl) for low animal fat intake (\leq 19.9% of energy) vs high animal fat intake (>19.9% of energy): 39.7 ± 0.02 vs 36.2 ± 0.03 for 'B1B1', 42.2 ± 0.04 vs 43.5 ± 0.03 for 'B2B2', $P_{\text{interaction}}$




Fig. 3 CETP–diet interaction studies and the interaction findings in multiple ethnicities

= 0.02; mean HDL (mg/dl) for low SFA intake ($\leq 11.47\%$ of energy) vs high SFA intake ($>11.47\%$ of energy): 39.8 ± 0.02 vs 36.2 ± 0.03 for ‘B1B1’, 42.2 ± 0.04 vs 43.8 ± 0.03 for ‘B2B2’, $P_{\text{interaction}} = 0.02$; mean HDL (mg/dl) for low MUFA intake ($\leq 12.75\%$ of energy) vs high MUFA intake ($>12.75\%$ of energy): 39.3 ± 0.03 vs 36.5 ± 0.02 for ‘B1B1’, 41.9 ± 0.03 vs 44.2 ± 0.03 for ‘B2B2’, $P_{\text{interaction}} = 0.04$. The difference in the findings might be due to the type of fat consumed since the Iranian study only considered total fat intake while the American study investigated types of fat. Furthermore, the variation in frequency of the TaqIB SNP might also contribute to the difference in the findings. In the Iranian study [15], only 8 out of 127 normolipidemic individuals had the ‘B1B1’ genotype, but in the American study [13] 192 out of 603 participants had the ‘B1B1’ genotype. Thus, while these two studies were both conducted in patients with T2D, there is a wide variation in frequency of the ‘B1B1’ genotype between the two studies and this affects the interpretation of the findings. In an animal study performed in feral adult male St. Kitts vervet monkeys (*Cercopithecus aethiops sabeus*) [44], SFA was shown to increase CETP activity, thereby reducing HDL levels which might explain the findings of the study in the American population [13]. However, in the animal study [44], the effect of SFA on CETP activity was only observed when cholesterol was added to the diet. SFA has also been shown to lower the number of LDL receptors in the liver, which slows the removal of apolipoprotein B (ApoB)–containing lipoproteins [45], with the resulting effect of a decrease in HDL levels.

It has also been demonstrated that the effect of dietary fat on CETP expression is not dependent solely on the composition of fat, but also on the amount of fat [46], although the mechanisms under which total fat affects CETP expression are still unclear [15]. A cross-sectional study of 2858 Chinese participants, 761 Malay participants and 588 Asian Indian participants [17] demonstrated that participants with ‘B2B2’ genotype had a significantly higher increase in HDL in response to a higher intake of dietary cholesterol compared to those with ‘B1B1’ and ‘B1B2’ genotypes, but the interaction was only significant in Asian Indians ($P_{\text{interaction}} = 0.0230$) and Malays ($P_{\text{interaction}} = 0.0460$). A cross-sectional study of 215 Mexican-Mestizos [47] also showed that a higher sucrose intake ($\geq 5\%$ of total energy per day) was linked to increased levels of total cholesterol and LDL in individuals with ‘B1B2’/‘B2B2’ genotype compared to those with ‘B1B1’ genotype (mean total cholesterol (mg/dl) (95% confidence interval): 200.19 (184.79–215.60) vs 165.55(142.21–188.89), $P_{\text{interaction}} = 0.0340$; mean LDL (mg/dl) (95% confidence interval): 128.64 (113.59–143.69) vs 99.29 (75.52–123.05), $P_{\text{interaction}} = 0.0370$). As this study [47] was the only one which investigated sucrose intake, and considering that the sample size was 215, further studies are needed to corroborate these findings.

Several studies have investigated the interaction between alcohol intake and TaqIB genotype on HDL, LDL and TG [48–51]. In a cross-sectional study of 758 healthy Chinese participants [48], individuals with ‘B1B1’ genotype who consumed any amount of alcohol

had higher HDL (mean HDL (mmol/l): 2.09 ± 0.46 vs 1.94 ± 0.38 ; $P_{\text{interaction}} < 0.01$), higher TG (mean TG (mmol/l): 1.42 ± 2.71 vs 0.94 ± 0.36 ; $P_{\text{interaction}} < 0.05$) and lower LDL (mean LDL (mmol/l): 2.24 ± 0.65 vs 2.65 ± 3.01 ; $P_{\text{interaction}} < 0.01$) compared to those with ‘B1B1’ genotype who did not drink alcohol. Those with ‘B1B2’ genotype who consumed any amount of alcohol also had higher HDL (mean HDL (mmol/l): 2.17 ± 0.55 vs 2.02 ± 0.50 ; $P_{\text{interaction}} < 0.05$) compared to individuals with ‘B1B2’ genotype who did not drink alcohol; and lower TG (mean TG (mmol/l): 1.01 ± 0.86 vs 1.42 ± 2.71 ; $P_{\text{interaction}} < 0.05$) compared to those with ‘B1B1’ who consumed any amount of alcohol. There were no significant interactions between alcohol intake and TG or HDL in participants with ‘B2B2’ genotype. This study also observed that ‘B2B2’ individuals who drank any amount of alcohol had lower LDL than ‘B2B2’ participants who did not drink alcohol (mean LDL in mmol/l: 2.20 ± 0.52 vs 2.41 ± 0.86 ; $P_{\text{interaction}} < 0.0500$), while there were no significant interactions between alcohol intake and LDL in those with ‘B1B2’ genotype. Similar findings were reported in a nested case-control study involving 505 patients with coronary heart disease (CHD) and 1010 healthy controls from different ethnicities in the US population [49] in which it was observed that, among healthy individuals, a higher intake of alcohol ($\geq 15\text{g/day}$) was linked to higher HDL in participants carrying the ‘B2’ allele compared to those with ‘B1B1’ genotype, with ‘B2B2’ individuals having the highest HDL ($P_{\text{interaction}} < 0.0100$). These findings are consistent with the results of a case-control study consisting of 608 Irish and French men with myocardial infarction (MI) and 742 healthy controls [51], which reported that, among individuals with a higher alcohol intake ($\geq 75\text{g/day}$), those carrying the ‘B2’ allele had higher mean plasma HDL (30% higher for ‘B2B2’ and 13% higher for ‘B1B2’) than those with the ‘B1B1’ genotype ($P_{\text{interaction}} < 0.0001$). Likewise, a cross-sectional study of 1729 Japanese participants [50] reported that, among women who consumed any amount of alcohol, those with ‘B2B2’ genotype had higher HDL than those with ‘B1B1’ or ‘B1B2’ genotype (mean HDL (mmol/l): 1.57 ± 0.03 for ‘B1B1’; 1.57 ± 0.03 for ‘B1B2’; 1.79 ± 0.06 for ‘B2B2’; $P_{\text{interaction}} = 0.0220$); while in men who consumed ≥ 2 drinks/day, those carrying the ‘B2’ allele had higher HDL than those with ‘B1B1’ genotype (mean HDL (mmol/l): 1.37 ± 0.03 for ‘B1B1’, 1.44 ± 0.03 for ‘B1B2’, 1.49 ± 0.05 for ‘B2B2’; $P_{\text{interaction}} = 0.0490$). These findings suggest that alcohol intake could alter lipid profiles by increasing HDL in both ‘B1’ and ‘B2’ carriers; however, the underlying mechanism is unclear and considering that alcohol intake has been linked to other health issues such as liver cirrhosis, the overall benefit needs to be carefully considered. Moreover, interaction between alcohol intake and TaqIB

genotype on blood lipids has been investigated by 12 studies and eight of the studies have not found significant interactions [13, 15, 52–57].

Six out of fourteen dietary intervention studies found significant interactions between TaqIB genotype, dietary factors and blood lipids. Three of the interactions were observed in participants carrying the ‘B2’ allele while the remaining three were reported in those with the ‘B1B1’ genotype. A 6-day dietary intervention study [58], using high carbohydrate/low-fat diet in 56 healthy Chinese individuals, showed that those carrying the ‘B2’ allele had higher HDL concentrations (mean HDL (mg/dl): 56.14 ± 10.69 after washout diet vs 59.77 ± 10.62 after high carbohydrate/low-fat diet; $P_{\text{interaction}} < 0.0500$) but the interaction was not observed in individuals with ‘B1B1’ genotype. As the duration of this intervention was only 6 days, intervention studies with longer duration are required to confirm the effect of carbohydrate on HDL in individuals carrying the ‘B2’ allele. In a meta-analysis of 26 dietary interventions using SFA, trans fat, dietary cholesterol and the coffee diterpene cafestol in 405 healthy Dutch participants over a 20-year period [59], participants with ‘B2B2’ genotype had a larger increase in HDL in response to SFA compared to those with ‘B1B1’ or ‘B1B2’ genotypes (mean change in HDL (mmol/l): 0.08 ± 0.02 for ‘B2B2’, 0.03 ± 0.01 for ‘B1B2’, 0.04 ± 0.02 for ‘B1B1’ genotype; $P = 0.0400$), while participants carrying the ‘B1’ allele had a smaller increase in LDL in response to dietary cholesterol than those with the ‘B2B2’ genotype (mean change in LDL (mmol/l): 0.27 ± 0.14 for ‘B1B1’, 0.35 ± 0.08 for ‘B1B2’, 0.75 ± 0.15 for ‘B2B2’; ‘B1B1’ vs ‘B2B2’, $P = 0.0300$; ‘B1B2’ vs ‘B2B2’, $P = 0.0100$). In an oral fat tolerance test performed in 80 Greek participants who were heterozygous for familial hypercholesterolemia (FH) and 11 control participants [60], it was demonstrated that, among participants in the FH group who showed an abnormal postprandial TG response (TG concentration of >220 mg/dl), men with the ‘B2’ allele had higher levels of TG than women with the ‘B2’ allele after 4 hours of fat intake (279 ± 95 vs 239 ± 65 mg/dl, $P = 0.0300$) but there were no reports of significant interactions in participants with ‘B1B1’ genotype.

Statistically significant interactions between carriers of the ‘B1’ allele and dietary factors were reported by three dietary intervention studies [43, 61, 62]. In a randomised triple-blind crossover trial performed in 95 Iranian patients with T2D and 73 healthy controls using three diets: sesame oil, canola oil and sesame-canola oil [61], it was demonstrated that, in the T2D group, those with ‘B1B1’ genotype had a significant reduction in lipid ratios after consuming sesame oil and sesame-canola oil (change in LDL:HDL (mg/dl): -1.29 , $P_{\text{interaction}} = 0.0270$; change in TC:HDL (mg/dl): -2.82 , $P_{\text{interaction}} = 0.0240$; and change in TG:HDL (mg/dl): -7.00 , $P_{\text{interaction}} = 0.0250$) but there were no reports of

significant reductions in lipid ratios in participants carrying the ‘B2’ allele. Another randomised controlled trial (RCT) performed in 85 New Zealander men with hypercholesterolemia, involving a 4-week healthy diet vs healthy diet plus two kiwi fruits per day [62], also showed that, among participants with ‘B1B1’ genotype, consumption of kiwi fruit resulted in lower TG:HDL ratio than the control diet (mean change in TG:HDL (mmol/l): -0.14 ± 0.51 for kiwifruit vs 0.09 ± 0.56 for control diet, $P = 0.03$; $P_{\text{interaction}} < 0.05$), while in individuals carrying the ‘B2’ allele, the interaction was not observed. Similar results were also observed in a crossover intervention conducted in Spanish prepubertal children with mild hypercholesterolemia, consisting of consumption of cow’s skim milk vs cow’s skim milk enriched with virgin olive oil for two periods of 6 weeks [43]. It was observed that intake of olive oil-enriched skim milk resulted in a larger increase in HDL and a decrease in LDL:HDL ratio in participants with ‘B1B1’ genotype compared to those carrying the ‘B2’ allele (mean change in HDL (mmol/l) (95% confidence interval): 0.179 (0.096 to 0.262) for ‘B1B1’ vs 0.089 (0.032 to 0.146) for carriers of ‘B2’, $P_{\text{interaction}} < 0.0010$; mean change in LDL:HDL ratio (mmol/l) (95% confidence interval): -0.470 (-0.729 to 0.211) for ‘B1B1’ vs -0.097 (-0.275 to 0.081) for carriers of ‘B2’, $P_{\text{interaction}} < 0.0010$). While these studies show that individuals with the ‘B1B1’ genotype could benefit from consuming these diets, the interactions were reported only in those with either T2D [61] or hypercholesterolemia [43, 62] indicating that these results may not apply to healthy participants and hence, this limits the wider application of the findings.

The TaqIB, located in intron 1 of the *CETP* gene, is considered to be non-functional and is believed to serve as a marker for functional SNPs in the promoter region [13, 17, 63]. The ‘B1’ allele differs from the ‘B2’ allele by the presence of a restriction site for TaqI endonuclease [17]. The ‘B1’ allele is believed to be associated with higher CETP activity, resulting in lower HDL and higher serum TG, and is considered a risk factor for dyslipidaemia [47]. This is supported by some of the studies as participants with the ‘B1B1’ genotype tended to have lower HDL [15, 17, 49, 56]. Nonetheless, the results suggest that people with this genotype can increase their HDL and modify their genetic risk by consuming sesame oil, canola oil, olive oil and kiwi fruit among others, although larger studies covering different ethnicities are warranted to tailor nutritional advice based on ethnicity and genetic profile.

SNP rs5882 (I405V G > A)

The SNP rs5882 (I405V) results in a substitution of valine (V) for isoleucine (I); hence, the ‘G’ allele is also called the ‘V’ allele while the ‘A’ allele is also known

as the ‘I’ allele. The frequency of the ‘V’ allele is 34% globally but in Africans it is 58%, while in Asians it is 48% and in Europeans it is 32% [64]. Six out of eight observational studies found statistically significant interactions between this SNP and dietary factors on blood lipids. A cross-sectional analysis of 101 individuals from different ethnicities in the US population [10•] showed that a higher MUFA intake ($>31\text{g/day}$) was associated with lower TG in participants carrying the minor allele (‘V’) ($P_{\text{interaction}} = 0.0060$) but there were no reports of significant interactions in individuals with ‘II’ genotype. A longitudinal study of 4700 Iranian participants over 3.6 years [65] reported that a higher MUFA intake was linked to increased levels of TG in participants carrying the ‘V’ allele (mean changes in TG (mg/dl) across quartiles of MUFA intake: -3.03 , 1.73 , 8.06 , 8.85 ; $P_{\text{interaction}} = 0.0010$), but the interaction was not observed in those with ‘II’ genotype. This study also observed that a higher intake of total fat correlated with increased levels of TG in those carrying the ‘V’ allele (mean changes in TG (mg/dl) across quartiles of total fat intake: -1.90 , 2.6 , 6.06 , 8.88 ; $P_{\text{interaction}} = 0.0010$) but the interaction was not significant in those with ‘II’ genotype. A higher carbohydrate intake was also found to be associated with decreased levels of TG in ‘V’ allele carriers (mean changes in TG (mg/dl) across quartiles of carbohydrate intake: 6.65 , 7.29 , 4.42 , -3.28 ; $P_{\text{interaction}} = 0.0100$) but the interaction was not significant in individuals with ‘II’ genotype [65]. Interactions with MUFA were also reported in a nested case-control of 441 Iranian participants with metabolic syndrome and 844 healthy controls [66] wherein carriers of the ‘V’ allele had a reduced risk of low HDL with a low intake of MUFA ($<8.4\%$ of energy) and an increased risk of low HDL with a higher intake of MUFA (9.6–11% of total energy intake) compared to those with ‘II’ genotype (odds ratio for low HDL across quartiles of MUFA intake: 0.49 , 0.66 , 0.88 , 0.66 for carriers of ‘V’ allele vs 1 , 0.61 , 0.62 , 0.68 for ‘II’ genotype; $P_{\text{interaction}} = 0.0200$). The findings of these studies suggest that the SNP rs5882 (I405V) may modify the link between fat intake and blood lipids. A higher intake of MUFA and total fat appears to be unfavourable in Iranian participants carrying the ‘V’ allele by leading to an increase in TG levels and the risk of low HDL while carbohydrate intake seems to be beneficial in reducing TG levels in these ‘V’ allele carriers [65, 66]. Conversely, the study in the US population [10•] implies MUFA is beneficial in individuals carrying the ‘V’ allele. As this study [10•] was performed in participants from different ethnicities, it is difficult to confirm ethnicity as a reason for the differential response to MUFA. Moreover, the study was performed in participants with overweight and obesity which could influence the findings since obesity is known to alter the interaction between diet and genotype

on lipids [10•]. Nonetheless, the Iranian case-control study [66] also involved participants with metabolic syndrome as well as healthy controls; but, the study did not report the findings for healthy controls. It has been demonstrated that *CETP* transgenic mice fed with MUFA had improved LDL receptor activity with a corresponding increase in the uptake of ApoB-containing lipoproteins by the liver [67], which could explain the reduction in TG levels associated with a high MUFA diet. The lipid-lowering effect of MUFA has also been linked to a decrease in expression of the transcription factor liver X receptor α (*LXR α*) which is involved in *CETP* activation [68]. Moreover, it has been argued that animal-based sources of MUFA also contain substantial amounts of SFA which could mask the effects of MUFA [69], implying that the source of MUFA needs to be taken into account when assessing the impact of MUFA on lipid-related outcomes.

In a cross-sectional study of Icelandic participants (152 men and 166 women) [70], alcohol intake was found to be associated with higher HDL in men with ‘VV’ genotype (13.7% higher HDL than ‘II’ genotype) compared to men with ‘II’ or ‘IV’ genotype ($P_{\text{interaction}} < 0.0200$) but the interaction was not statistically significant in women. Interactions with HDL were also observed in a cross-sectional study of 553 Inuit participants [71] in which higher levels of omega 3 polyunsaturated fatty acids (n-3 PUFA) in red blood cells (RBCs) was associated with higher HDL in participants carrying the major allele (‘I’) compared to those with ‘VV’ genotype (β (mmol/l) = 0.0263 ± 0.0115 for ‘IV’ genotype, β (mmol/l) = 0.0017 ± 0.0131 for ‘II’ genotype; $P_{\text{interaction}} = 0.0271$). The study also found that n-3 PUFA in RBCs had a negative correlation with total cholesterol in participants with ‘II’ genotype compared to those with ‘VV’ or ‘IV’ genotype (β (mmol/l) = -0.0290 ± 0.0307 ; $P_{\text{interaction}} = 0.0334$). In another cross-sectional study of 553 Inuit participants [16], individuals with ‘II’ genotype had a greater increase in total cholesterol with a higher intake of total fat than those with ‘VV’ or ‘IV’ genotype (β (mmol/l) = 0.0024 ± 0.0026 ; $P_{\text{interaction}} = 0.0460$). These findings imply that while n-3 PUFA intake was beneficial for Inuit participants carrying the ‘I’ allele [71], higher total fat intake was not favourable for these participants [16]. PUFA is believed to promote the synthesis of LDL receptors which has the effect of increasing hepatic uptake of ApoB-containing lipoproteins [72], thereby raising the levels of HDL. To understand how PUFA affects regulation of the *CETP* gene, a study [73] was conducted in *CETP* transgenic mice which demonstrated that n-3 PUFA resulted in elevated *CETP* messenger RNA (mRNA) and protein levels, possibly by being a ligand for peroxisome proliferator-activated receptors α (*PPAR α*), which is involved in the regulation of lipid-related genes [73]. However, increased *CETP* activity is known to have an inverse effect on HDL levels and does not explain the

beneficial effect on HDL observed in the Inuit study. This raises the question of whether particular *CETP* SNPs dictate the response of the *CETP* protein to n-3 PUFA.

Only one of the six dietary intervention studies reported significant interactions between the I405V SNP and dietary factors on blood lipids. In this study [74], Canadian monozygotic twins (12 pairs) who were overfed by 1000 kcal per day for a period of 100 days showed a significant decrease in HDL, HDL₂ and HDL₃ in those with ‘II’ genotype compared to individuals with ‘VV’ genotype (mean change in HDL (mmol/l): -0.12 ± 0.04 vs 0.02 ± 0.04 , $P = 0.02$; mean change in HDL₂ (mmol/l): -0.08 ± 0.03 vs 0.03 ± 0.03 , $P = 0.04$; mean change in HDL₃ (mmol/l): -0.04 ± 0.02 vs -0.004 ± 0.02 , $P = 0.0020$), but there were no reports of significant interactions in individuals with ‘IV’ genotype. The ‘II’ genotype of SNP rs5882 is believed to affect the ability of the *CETP* protein to mediate the exchange of cholesteryl esters for TG, resulting in increased TG concentrations [66], although this SNP has not been reported by any of the 32 GWASs to impact on lipids.

It has also been shown that the ‘VV’ genotype of the SNP rs5882 is associated with lower plasma *CETP* levels and increased HDL concentration [75]; however, baseline HDL data for participants with the ‘VV’ genotype was not available for all the studies because there were not enough participants with the ‘VV’ genotype in the two Iranian studies [65, 66]. Also, in the two Inuit studies [16, 71], baseline HDL data was not recorded separately for ‘VV’, ‘IV’ or ‘II’ genotype. However, in the Icelandic study [70], those with the ‘VV’ genotype had higher baseline HDL levels. Overall, the findings indicate that the SNP rs5882 may modify dietary response to lipids, but further studies are needed to clarify the differences in the results of some of the studies.

SNP rs3764261 (C > A)

Significant interactions between dietary factors and SNP rs3764261 on blood lipids were observed in two out of four observational studies. In a longitudinal study of 4700 Iranian participants over 3.6 years [65], it was reported that a higher fish intake was associated with a larger decrease in total cholesterol (TC) in participants carrying the minor allele (‘A’) (mean changes in TC (mg/dl) with quartiles of fish intake: 8.02, 6.93, 6.54, 5.58) compared to those carrying two copies of the major allele (‘C’) (mean changes in TC (mg/dl) with quartiles of fish intake: 3.65, 6.62, 4.57, 8.93) ($P_{\text{interaction}} = 0.02$). Interactions with fat intake were also observed in a cross-sectional study of 3342 Indian participants [76] in which a high dietary fat intake (≥ 76.98 g/day) was associated with increased levels of TC (β (mmol/l) = 0.097 ± 0.041 ; $P_{\text{interaction}} = 0.018$) and LDL (β (mmol/l) = 0.085 ± 0.041 ; $P_{\text{interaction}} = 0.0420$) in participants carrying the ‘A’ allele but there were no reports of interactions in

those with ‘CC’ genotype. A high-fat diet has been demonstrated to increase CETP activity in transgenic mice [77] which has the effect of increasing TC and LDL and could account for the findings reported. Moreover, the SNP rs3764261 (C > A) is located in the 5¹ region of the *CETP* gene and has been shown to regulate expression of the gene, the ‘C’ allele being associated with increased *CETP* expression and reduced HDL levels [78].

Two dietary intervention studies reported statistically significant interactions between the SNP rs3764261 and dietary factors on blood lipids. In a prospective, randomized, single-blind controlled dietary intervention trial carried out in 424 Spanish patients who had acute coronary syndrome (ACS) or CHD and also had metabolic syndrome [14], wherein participants consumed either a Mediterranean diet or a low-fat diet, it was observed that, after 1 year, consumption of Mediterranean diet was associated with higher HDL and lower TG in participants carrying the ‘A’ allele compared to those with ‘CC’ genotype (mean HDL (mg/dl): 41 vs 38, $P_{\text{interaction}} = 0.0060$; mean TG (mg/dl): 130 vs 146, $P_{\text{interaction}} = 0.0400$). This finding indicates that Mediterranean diet might be beneficial in increasing HDL in Spanish participants with ACS or CHD who carry the ‘A’ allele [14]; however, this finding might not be applicable to healthy individuals. In another study which was performed on participants from different ethnicities and involved a 2-year randomised weight loss trial, consisting of low-fat diet (20% fat) vs high-fat diet (40% fat), and a 2-year RCT consisting of low-fat diet (30% fat) vs low carbohydrate (high-fat) diet [46], the combined results of the two interventions showed that, among participants with ‘CC’ genotype, those in the high-fat diet group had a higher increase in HDL (11.7 vs 4.5%; $P_{\text{interaction}} = 0.01$) and a larger decrease in TG (–25.1 vs –11.7%; $P_{\text{interaction}} = 0.0007$) than those in the low-fat diet group, but there were no significant interactions in participants with ‘CA’ or ‘AA’ genotype. These results suggest that a high-fat diet (40% fat) in individuals from different ethnicities who have the ‘CC’ genotype might contribute to increased HDL and reduced TG levels [46] although the findings are not in agreement with the study performed in *CETP* transgenic mice [77] in which a high-fat diet resulted in increased CETP activity which lowered HDL levels. Considering that this was a weight loss intervention, it is unclear whether the changes in lipid levels were due to the high-fat diet or the loss of weight or both since physical activity has been shown to interact with genetic risk score and impact on waist-hip ratio [79]. Moreover, the ‘C’ allele of the SNP rs3764261 is regarded as a significant risk factor for low HDL [78, 80] although it has been demonstrated that this risk can be overcome by weight gain prevention [78]. The SNP rs3764261 has also been shown by GWASs to influence HDL levels in Asian Indians [19, 28], Japanese [26, 31], African-American [29], Chinese [20], Lebanese [21]

and Finnish [35] but the evidence indicates that this SNP has not been extensively studied by gene–diet interaction studies. Therefore, further studies in different ethnicities are required to confirm the effect of the SNP in modifying dietary response to lipids.

C-629A (SNP rs1800775 C > A)

The SNP rs1800775 has been shown to be associated with HDL in seven of the nineteen GWASs [19, 22, 24, 31, 34, 35, 37]. Two out of five observational studies reported significant interactions between dietary factors and the SNP rs1800775 (C-629A) on blood lipids. In a cross-sectional study of 9075 Taiwanese participants [81], consumption of coffee was found to be associated with lower HDL in women carrying the minor allele (‘C’) compared to women with ‘AA’ genotype (β (mg/dl) = –1.8095 for ‘AC’ genotype, β (mg/dl) = –2.8151 for ‘CC’ genotype; $P_{\text{interaction}} < 0.0001$), and in men carrying the ‘C’ allele compared to men with the ‘AA’ genotype (β (mg/dl) = –1.9623 for ‘AC’ genotype, β (mg/dl) = –2.7154 for ‘CC’ genotype; $P_{\text{interaction}} < 0.0001$). A case-control study consisting of 568 Irish and French men with MI and 668 healthy controls [82] showed that, among individuals carrying the major allele (‘A’), alcohol consumption was associated with higher HDL in healthy participants ($P_{\text{interaction}} < 0.0020$) and in patients who were not treated with lipid-lowering medication ($P_{\text{interaction}} < 0.0010$), while in individuals with ‘CC’ genotype, there was no association between alcohol intake and HDL. The results suggest that dietary factors other than fat intake may also play a role in modulating lipid levels, but these interactions need to be explored further to allow for comparison of results across multiple ethnic groups. The SNP rs1800775 (C-629A) is located in the promoter region of the *CETP* gene and the ‘A’ allele is associated with reduced *CETP* expression and higher HDL levels [17]. The ‘A’ allele of SNP rs1800775 (C-629A) is in a high degree of linkage disequilibrium with the ‘B2’ allele of SNP TaqIB and it is believed that this association is responsible for the protective effect of the ‘B2’ allele [17]. However, some are of the view that there might be other functional SNPs that are in linkage disequilibrium with TaqIB apart from SNP rs1800775 (C-629A) but it is unclear what these SNPs are [13, 63]. Moreover, despite the SNP rs1800775 (C-629A) being reported by several GWASs to be associated with blood lipids, this SNP has not been extensively studied in gene–diet interaction studies. To date, only one dietary intervention study [83] investigated the SNP rs1800775 (C-629A) which also failed to demonstrate any significant SNP–diet interactions on lipids. This study was an RCT performed in 490 participants from different ethnicities in the UK population and involved a reference diet (~18% SFA, 12% MUFA, 38% total fat, 45% carbohydrate (CHO)) for 4 weeks, followed by 1 of three

diets: a MUFA diet (~10% SFA, 20% MUFA, 38% total fat, 45% CHO); a low-fat diet (~10% SFA, 11% MUFA, 28% total fat, 55% CHO); or the reference diet for 24 weeks. The findings overall indicate that further large studies are needed to confirm the effect of the SNP rs1800775 in altering lipid profiles in response to diet.

Other SNPs

Other *CETP* SNPs which have been reported to interact with dietary factors and influence blood lipids are SNPs rs183130 (C-4502T), rs4783961 (G-971A), rs289714 (C>T) and rs1800774 (C > A). In the cross-sectional study of 553 Inuit participants [84], higher levels of n-3 PUFA in RBCs was linked to lower TC levels in participants carrying the minor allele ('T') of the SNP rs183130 (C-4502T) compared to those with 'CC' genotype (β (mmol/l) = -0.0632 ± 0.0241 for 'CT' genotype, β (mmol/l) = -0.0421 ± 0.0343 for 'TT' genotype; $P_{\text{interaction}} = 0.0326$); and lower TG levels in those with the 'TC' genotype of the SNP rs183130 (C-4502T) compared to individuals with 'TT' genotype (β (mmol/l) = -0.0095 ± 0.0051 vs β (mmol/l) = 0.0073 ± 0.0073 ; $P_{\text{interaction}} = 0.0300$), while there were no reports of significant interactions between n-3 PUFA in RBCs and TG in participants with 'CC' genotype. This study also reported that individuals with the 'GA' genotype of the SNP rs4783961 (G-971A) who had higher levels of n-3 PUFA in RBCs had lower TG levels (β (mmol/l) = -0.0106 ± 0.0057 ; $P_{\text{interaction}} = 0.0032$) and lower TC:HDL ratio (β (mmol/l) = -0.0055 ± 0.0033 ; $P_{\text{interaction}} = 0.0483$) compared to participants with 2 copies of the minor allele ('A') of the SNP rs4783961 (G-971A). These findings point to a beneficial role of PUFA in Inuit participants carrying the 'T' allele of the SNP rs183130(C-4502T) and the 'G' allele of the SNP rs4783961 (G-971A). PUFA is believed to improve the breakdown of ApoB-containing particles, thereby reducing TG concentrations [66], which is consistent with this finding. However, in a cross-sectional study of 821 participants who were normal glucose tolerant and 861 participants with T2D, involving the transcription factor 7-like 2 (*TCF7L2*) gene [85], higher PUFA intake (mean PUFA intake of 29g/day) was linked to 1.64 mg/dl lower HDL while lower PUFA intake (mean PUFA intake of 9g/day) was associated with 1.96 mg/dl higher HDL in Asian Indian participants carrying the 'T' allele of the *TCF7L2* SNP rs12255372 compared to those with the 'GG' genotype ($P_{\text{interaction}} < 0.0001$). In another cross-sectional study involving 101 participants of different ethnicities in the US population [10•], it was reported that, among participants with two copies of the major allele ('A') of the SNP rs289714, those who consumed >92 g of total fat per day had lower TG levels (103 ± 63 mg/dl) than those who consumed <31 g of total fat per day (135 ± 15 mg/dl) ($P_{\text{interaction}} = 0.0010$). The interaction

was significant for both the dominant and recessive modes of inheritance ($P_{\text{interaction}} = 0.0010$ and $P_{\text{interaction}} = 0.0230$ respectively), but there were no reports of significant interactions in individuals with 'GG' genotype. In another cross-sectional study of 1315 Spanish participants [86], higher plasma selenium levels were found to be associated with elevated LDL levels in all the three genotypes of the SNP rs1800774 but participants with two copies of the major allele ('C') had lower LDL compared to those with 'CT' and 'TT' genotypes (odds ratio per an interquartile range increase in plasma selenium (95% confidence interval): 0.97 (0.74 to 1.27) for 'CC', 1.76 (1.38 to 2.25) for 'CT', 3.20 (1.93 to 5.28) for 'TT' genotype; $P_{\text{interaction}} = 0.0002$). Selenium was also reported to be associated with lipid levels in a systematic review and meta-analysis [87], but it was shown to be linked to significant improvement in the levels of TC and TG and had no significant effect on LDL levels. A systematic review published in 2017, in which the results of 23 gene–diet interaction studies involving *CETP* were analysed [88], concluded that SNPs in the *CETP* gene may influence the effect of dietary factors on metabolic traits but that the findings from these studies were inconsistent and suggest that multiple factors might be involved.

Conclusion

In summary, this review has identified statistically significant interactions between 17 dietary factors and 8 SNPs in the *CETP* gene on blood lipids in the following populations: Mexican, Iranian, Spanish, White American, Chinese, Malay, Indian, Irish, French, Japanese, New Zealander, Dutch, Greek, Icelandic, Inuit, Canadian, Taiwanese and residents of the USA. The SNPs showing significant interactions with dietary factors (such as total fat intake, MUFA, n-3 PUFA, Mediterranean diet, olive oil and sesame-canola oil) were TaqIB (rs708272 G > A); rs5882 (I405V); rs3764261 (C > A); rs1800775 (C-629A); rs183130(C-4502T); rs4783961 (G-971A); rs289714 (C>T) and rs1800774 (C > A). The macronutrient investigated by majority of the studies was dietary fat, comprising of total fat, SFA, MUFA and PUFA. Total fat intake accounted for majority of the interactions across different SNPs, being associated with unfavourable lipid outcomes in some individuals but not others.

Studies reporting significant interactions in individuals with the B1B1 genotype of the SNP TaqIB (rs708272) have been performed in participants with either T2D or hypercholesterolemia. Similarly, those reporting significant interactions in individuals carrying the 'V' allele of the SNP rs5882 have been conducted in participants with overweight and obesity or metabolic syndrome. Moreover, some of the significant interactions involving the SNP rs3764261 have also been reported in patients with ACS or CHD, suggesting that some of the findings of these studies may not apply to healthy participants.

Overall, the findings suggest that *CETP* SNPs might alter blood lipid profiles by modifying responses to diet, but further large studies in multiple ethnic groups are warranted to identify individuals at risk of adverse lipid response to diet which is essential in developing dietary guidelines that are tailored to specific groups of people. Information on the underlying genetic factors for dyslipidaemia will also contribute to improved understanding of the mechanisms involved, which is central to the development of effective preventative strategies as well as identifying areas for further research.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s11883-022-00987-y>.

Acknowledgements Prof. Karani S. Vimalaswaran acknowledges support from the British Nutrition Foundation and the Medical Research Council (grant # H5457400).

Author Contribution RW extracted and interpreted *CETP* genetic variants related to gene–diet interactions on lipids and drafted the manuscript, and this was double-checked by KSV and AAW. KSV conceived and designed the review and interpreted the results. All authors were involved in drafting the manuscript and revising it critically for intellectual content. All authors have approved the final version of the manuscript.

Declarations

Conflict of Interest The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. World Health Organisation. The top 10 causes of death. In: Factsheets. 2020. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> Accessed 15 March 2021.
2. Vimalaswaran KS, Minihane AM, Li Y, Gill R, Lovegrove JA, Williams CM, et al. The APOB insertion/deletion polymorphism (rs17240441) influences postprandial lipaemia in healthy adults. *Nutr Metab*. 2015;12:7–7. <https://doi.org/10.1186/s12986-015-0002-9>.
3. Clifton NA, Copples T. Managing dyslipidemia for CVD prevention: a review of recent clinical practice guidelines. *Nurse Pract*. 2019;44(1):8–16. https://journals.lww.com/tnpj/Fulltext/2019/01000/Managing_dyslipidemia_for_CVD_prevention__A_review.2.aspx
4. Rodriguez A, Trigatti BL, Mineo C, Knaack D, Wilkins JT, Sahoo D, et al. Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop. *Arterioscler Thromb Vasc Biol*. 2019;39(12):2457–67. <https://doi.org/10.1161/ATVBAHA.119.313340>.
- 5.●● Vimalaswaran KS. A nutrigenetics approach to study the impact of genetic and lifestyle factors on cardiometabolic traits in various ethnic groups: findings from the GeNuLine Collaboration. *Proc Nutr Soc*. 2020;79(2):194–204. <https://doi.org/10.1017/S0029665119001186>. **Findings from this study indicate that the effect of gene-diet interactions varies in different ethnic groups.**
6. Vimalaswaran KS, Cavadino A, Berry DJ, Jorde R, Dieffenbach AK, Lu C, et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a Mendelian randomisation study. *Lancet Diabetes Endocrinol*. 2014;2(9):719–29. [https://doi.org/10.1016/s2213-8587\(14\)70113-5](https://doi.org/10.1016/s2213-8587(14)70113-5).
7. Vimalaswaran KS, Bodhini D, Lakshmi Priya N, Ramya K, Anjana RM, Sudha V, et al. Interaction between FTO gene variants and lifestyle factors on metabolic traits in an Asian Indian population. *Nutr Metab (Lond)*. 2016;13:39. <https://doi.org/10.1186/s12986-016-0098-6>.
8. Ayyappa KA, Shatwan I, Bodhini D, Bramwell LR, Ramya K, Sudha V, et al. High fat diet modifies the association of lipoprotein lipase gene polymorphism with high density lipoprotein cholesterol in an Asian Indian population. *Nutr Metab (Lond)*. 2017;14:8. <https://doi.org/10.1186/s12986-016-0155-1>.
9. Shatwan IM, Winther KH, Ellahi B, Elwood P, Ben-Shlomo Y, Givens I, et al. Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors. *Lipids Health Dis*. 2018;17(1):98. <https://doi.org/10.1186/s12944-018-0744-2>.
- 10.● Hannon BA, Edwards CG, Thompson SV, Burke SK, Burd NA, Holscher HD, et al. Genetic variants in lipid metabolism pathways interact with diet to influence blood lipid concentrations in adults with overweight and obesity. *Lifestyle Genom*. 2020;13(6):155–163. <https://doi.org/10.1159/000507021>. **Findings from this study suggest that monounsaturated fatty acids might interact with genetic factors to influence the levels of triglycerides in individuals who are overweight or obese.**
11. Barter PJ, Kastelein JJP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. *J Am Coll Cardiol*. 2006;47(3):492–9. <https://doi.org/10.1016/j.jacc.2005.09.042>.
12. Barter PJ. The causes and consequences of low levels of high density lipoproteins in patients with diabetes. *Diabetes Metab J*. 2011;35(2):101–6. <https://doi.org/10.4093/dmj.2011.35.2.101>.
13. Li TY, Zhang C, Asselbergs FW, Qi L, Rimm E, Hunter DJ, et al. Interaction between dietary fat intake and the cholesterol ester transfer protein TaqIB polymorphism in relation to HDL-cholesterol concentrations among US diabetic men. *Am J Clin Nutr*. 2007;86(5):1524–9. <https://doi.org/10.1093/ajcn/86.5.1524>.
14. Garcia-Rios A, Alcalá-Díaz JF, Gómez-Delgado F, Delgado-Lista J, Marín C, León-Acuña A, et al. Beneficial effect of CETP

- gene polymorphism in combination with a Mediterranean diet influencing lipid metabolism in metabolic syndrome patients: CORDIOPREV study. *Clin Nutr.* 2018;37(1):229–34. <https://doi.org/10.1016/j.clnu.2016.12.011>.
15. Kalantar Z, Eshraghian MR, Sotoudeh G, Djalali M, Mansouri A, Alvandi E, et al. Differences in the interaction between CETP Taq1B polymorphism and dietary fat intake on lipid profile of normolipidemic and dyslipidemic patients with type 2 diabetes mellitus. *Clin Nutr.* 2018;37(1):270–5. <https://doi.org/10.1016/j.clnu.2016.12.024>.
 16. Rudkowska I, Dewailly E, Hegele RA, Boiteau V, Dubé-Linteau A, Abdous B, et al. Gene-diet interactions on plasma lipid levels in the Inuit population. *Br J Nutr.* 2013;109(5):953–61. <https://doi.org/10.1017/s0007114512002231>.
 17. Tai ES, Ordovas JM, Corella D, Deurenberg-Yap M, Chan E, Adiconis X, et al. The Taq1B and -629C>A polymorphisms at the cholesteryl ester transfer protein locus: associations with lipid levels in a multiethnic population. The 1998 Singapore National Health Survey. *Clin Genet.* 2003;63(1):19–30. <https://doi.org/10.1034/j.1399-0004.2003.630104.x>.
 18. Barter Philip J, Brewer HB, Chapman MJ, Hennekens Charles H, Rader Daniel J, Tall Alan R. Cholesteryl ester transfer protein. *Arterioscler Thromb Vasc Biol.* 2003;23(2):160–7. <https://doi.org/10.1161/01.ATV.0000054658.91146.64>.
 19. Khushdeep B, Prasad G, Giri AK, Kausar Y, Upadhyay M, Basu A, et al. Genome-wide association study of blood lipids in Indians confirms universality of established variants. *J Hum Genet.* 2019;64(6):573–87. <https://doi.org/10.1038/s10038-019-0591-7>.
 20. Zhou L, He M, Mo Z, Wu C, Yang H, Yu D, et al. A genome wide association study identifies common variants associated with lipid levels in the Chinese population. *PLoS ONE.* 2013;8(12). <https://doi.org/10.1371/journal.pone.0082420>
 21. Deek R, Nasser J, Ghanem A, Mardelli M, Khazen G, Salloum AK, et al. Genome-wide association analysis of HDL-C in a Lebanese cohort. *PLoS ONE.* 2019;14(6):e0218443. <https://doi.org/10.1371/journal.pone.0218443>.
 22. Kathiresan S, Melander O, Guiducci C, Surti A, Burt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet.* 2008;40(2):189–97. <https://doi.org/10.1038/ng.75>.
 23. Oh SW, Lee JE, Shin E, Kwon H, Choe EK, Choi SY, et al. Genome-wide association study of metabolic syndrome in Korean populations. *PLoS ONE.* 2020;15(1):e0227357. <https://doi.org/10.1371/journal.pone.0227357>.
 24. Wu Y, Marvelle AF, Li J, Croteau-Chonka DC, Feranil AB, Kuzawa CW, et al. Genetic association with lipids in Filipinos: waist circumference modifies an APOA5 effect on triglyceride levels. *J Lipid Res.* 2013;54(11):3198–205. <https://doi.org/10.1194/jlr.P042077>.
 25. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, Ripatti S, et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. *Arterioscler Thromb Vasc Biol.* 2010;30(11):2264–76. <https://doi.org/10.1161/atvbaha.109.201020>.
 26. Hiura Y, Shen CS, Kokubo Y, Okamura T, Morisaki T, Tomoike H, et al. Identification of genetic markers associated with high-density lipoprotein-cholesterol by genome-wide screening in a Japanese population: the Suita study. *Circ J.* 2009;73(6):1119–26. <https://doi.org/10.1253/circj.08-1101>.
 27. Smith EN, Chen W, Kähönen M, Kettunen J, Lehtimäki T, Peltonen L, et al. Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study. *PLoS Genet.* 2010;6(9):e1001094. <https://doi.org/10.1371/journal.pgen.1001094>.
 28. Zabaneh D, Balding DJ. A genome-wide association study of the metabolic syndrome in Indian Asian men. *PLoS ONE.* 2010;5(8):e11961. <https://doi.org/10.1371/journal.pone.0011961>.
 29. Lettre G, Palmer CD, Young T, Ejebe KG, Allayee H, Benjamin EJ, et al. Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARE Project. *PLoS Genet.* 2011;7(2):e1001300. <https://doi.org/10.1371/journal.pgen.1001300>.
 30. Carlson JC, Weeks DE, Hawley NL, Sun G, Cheng H, Naseri T, et al. Genome-wide association studies in Samoans give insight into the genetic architecture of fasting serum lipid levels. *J Hum Genet.* 2020. <https://doi.org/10.1038/s10038-020-0816-9>.
 31. Kurano M, Tsukamoto K, Kamitsuji S, Kamatani N, Hara M, Ishikawa T, et al. Genome-wide association study of serum lipids confirms previously reported associations as well as new associations of common SNPs within PCSK7 gene with triglyceride. *J Hum Genet.* 2016;61(5):427–33. <https://doi.org/10.1038/jhg.2015.170>.
 32. Coram MA, Duan Q, Hoffmann TJ, Thornton T, Knowles JW, Johnson NA, et al. Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations. *Am J Hum Genet.* 2013;92(6):904–16. <https://doi.org/10.1016/j.ajhg.2013.04.025>.
 33. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet.* 2009;41(1):47–55.
 34. Adeyemo A, Bentley AR, Meilleur KG, Doumatey AP, Chen G, Zhou J, et al. Transferability and fine mapping of genome-wide associated loci for lipids in African Americans. *BMC Med Genet.* 2012;13:88. <https://doi.org/10.1186/1471-2350-13-88>.
 35. Sabatti C, Service SK, Hartikainen A-L, Pouta A, Ripatti S, Brodsky J, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. *Nat Genet.* 2009;41(1):35–46. <https://doi.org/10.1038/ng.271>
 36. Heid IM, Boes E, Müller M, Kollerits B, Lamina C, Coassin S, et al. Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions. *Circ Cardiovasc Genet.* 2008;1(1):10–20. <https://doi.org/10.1161/CIRCGENETICS.108.776708>
 37. Saxena R, Voight BF, Lyssenko V, Burt NP, de Bakker PIW, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science.* 2007;316(5829):1331–6. <https://doi.org/10.1126/science.1142358>.
 38. Weissglas-Volkov D, Aguilar-Salinas CA, Nikkola E, Deere KA, Cruz-Bautista I, Arellano-Campos O, et al. Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. *J Med Genet.* 2013;50(5):298–308. <https://doi.org/10.1136/jmedgenet-2012-101461>.
 39. Chasman DI, Paré G, Mora S, Hopewell JC, Peloso G, Clarke R, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis: e1000730. *PLoS Genet.* 2009;5(11). <https://doi.org/10.1371/journal.pgen.1000730>
 40. Tan A, Sun J, Xia N, Qin X, Hu Y, Zhang S, et al. A genome-wide association and gene-environment interaction study for serum triglycerides levels in a healthy Chinese male population. *Hum Mol Genet.* 2012;21(7):1658–64. <https://doi.org/10.1093/hmg/ddr587>.
 41. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.

- Am J Hum Genet. 2008;82(1):139–49. <https://doi.org/10.1016/j.ajhg.2007.11.001>.
42. Frances E, Carrasco P, Sorli JV, Ortega C, Portoles O, Rubio MM, et al. Mo-P1:9 Impact of APOE, APOA5 and CETP polymorphism on plasma lipid concentrations and response to a Mediterranean diet in the PREDIMED study. *Atheroscler Suppl*. 2006;7(3):47. [https://doi.org/10.1016/S1567-5688\(06\)80146-7](https://doi.org/10.1016/S1567-5688(06)80146-7).
 43. Estévez-gonzález MD, Saavedra-santana P, López-ríos L, Chirino R, Cebrero-garcía E, Peña-quintana L, et al. HDL cholesterol levels in children with mild hypercholesterolemia: effect of consuming skim milk enriched with olive oil and modulation by the TAQ1B polymorphism in the CETP gene. *Ann Nutr Metab*. 2010;56(4):288–93. <https://doi.org/10.1159/000290405>.
 44. Fusegawa Y, Kelley KL, Sawyer JK, Shah RN, Rudel LL. Influence of dietary fatty acid composition on the relationship between CETP activity and plasma lipoproteins in monkeys. *J Lipid Res*. 2001;42(11):1849–57.
 45. Mustad VA, Ellsworth JL, Cooper AD, Kris-Etherton PM, Etherton TD. Dietary linoleic acid increases and palmitic acid decreases hepatic LDL receptor protein and mRNA abundance in young pigs. *J Lipid Res*. 1996;37(11):2310–23.
 46. Qi Q, Durst R, Schwarzfuchs D, Leitersdorf E, Shpitzen S, Li Y, et al. CETP genotype and changes in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT randomized trials. *J Lipid Res*. 2015;56(3):713–21. <https://doi.org/10.1194/jlr.P055715>.
 47. Campos-Perez W, Perez-Robles M, Torres-Castillo N, Rodríguez-Reyes SC, De la Cerda Trujillo LF, Navarro-Muñiz E, et al. Physical inactivity and excessive sucrose consumption are associated with higher serum lipids in subjects with Taq1B CETP polymorphism. *J Hum Nutr Diet*. 2020;33(3):299–307. <https://doi.org/10.1111/jhn.12747>.
 48. Zhou Y, Yin R, Deng Y, Li Y, Wu J. Interactions between alcohol intake and the polymorphism of rs708272 on serum high-density lipoprotein cholesterol levels in the Guangxi Hei Yi Zhuang population. *Alcohol*. 2008;42(7):583–91. <https://doi.org/10.1016/j.alcohol.2008.08.004>.
 49. Jensen MK, Mukamal KJ, Overvad K, Rimm EB. Alcohol consumption, Taq1B polymorphism of cholesteryl ester transfer protein, high-density lipoprotein cholesterol, and risk of coronary heart disease in men and women. *Eur Heart J*. 2008;29(1):104–12. <https://doi.org/10.1093/eurheartj/ehm517>.
 50. Tsujita Y, Nakamura Y, Zhang Q, Tamaki S, Nozaki A, Amamoto K, et al. The association between high-density lipoprotein cholesterol level and cholesteryl ester transfer protein Taq1B gene polymorphism is influenced by alcohol drinking in a population-based sample. *Atherosclerosis*. 2007;191(1):199–205. <https://doi.org/10.1016/j.atherosclerosis.2006.03.028>.
 51. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. *J Clin Invest*. 1995;96(3):1664–71. <https://doi.org/10.1172/jci118207>.
 52. Hannuksela ML, Liinamaa MJ, Kesäniemi YA, Savolainen MJ. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. *Atherosclerosis*. 1994;110(1):35–44. [https://doi.org/10.1016/0021-9150\(94\)90065-5](https://doi.org/10.1016/0021-9150(94)90065-5).
 53. Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. *Ann Hum Genet*. 2002;66(Pt 2):111–24. <https://doi.org/10.1017/s0003480002001057>.
 54. Volcik K, Ballantyne CM, Pownall HJ, Sharrett AR, Boerwinkle E. Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study. *J Stud Alcohol Drugs*. 2007;68(4):485–492. <https://doi.org/10.15288/jsad.2007.68.485>.
 55. Freeman DJ, Griffin BA, Holmes AP, Lindsay GM, Gaffney D, Packard CJ, et al. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. *Arterioscler Thromb*. 1994;14(3):336–344. <https://doi.org/10.1161/01.atv.14.3.336>.
 56. Corella D, Carrasco P, Amiano P, Arriola L, Chirlaque MD, Huerta JM, et al. Common cholesteryl ester transfer protein gene variation related to high-density lipoprotein cholesterol is not associated with decreased coronary heart disease risk after a 10-year follow-up in a Mediterranean cohort: modulation by alcohol consumption. *Atherosclerosis*. 2010;211(2):531–8. <https://doi.org/10.1016/j.atherosclerosis.2010.03.026>.
 57. Corella D, Carrasco P, Fitó M, Martínez-González MA, Salas-Salvadó J, Arós F, et al. Gene-environment interactions of CETP gene variation in a high cardiovascular risk Mediterranean population. *J Lipid Res*. 2010;51(9):2798–807. <https://doi.org/10.1194/jlr.P005199>.
 58. Du J, Fang DZ, Lin J, Xiao LY, Zhou XD, Shigdar S, et al. Taq1B polymorphism in the CETP gene modulates the impact of HC/LF diet on the HDL profile in healthy Chinese young adults. *J Nutr Biochem*. 2010;21(11):1114–9. <https://doi.org/10.1016/j.jnutbio.2009.09.009>.
 59. Weggemans RM, Zock PL, Ordovas JM, Ramos-Galluzzi J, Katan MB. Genetic polymorphisms and lipid response to dietary changes in humans. *Eur J Clin Invest*. 2001;31(11):950–7. <https://doi.org/10.1046/j.1365-2362.2001.00906.x>.
 60. Anagnostopoulou KK, Kolovou GD, Kostakou PM, Mihas C, Hatzigeorgiou G, Marvaki C, et al. Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia. *Lipids Health Dis*. 2009;8:24. <https://doi.org/10.1186/1476-511x-8-24>.
 61. Ramezani-Jolfaie N, Aghaei S, Yazd EF, Moradi A, Mozaffari-Khosravi H, Amiri M, et al. The combined effects of cholesteryl ester transfer protein (CETP) Taq1B gene polymorphism and canola, sesame and sesame-canola oils consumption on metabolic response in patients with diabetes and healthy people. *J Cardiovasc Thorac Res*. 2020;12(3):185–194,194A–194C. <https://doi.org/10.34172/jcvtr.2020.32>.
 62. Gammon CS, Minihane AM, Kruger R, Conlon CA, von Hurst PR, Jones B, et al. Taq1B polymorphism in the cholesteryl ester transfer protein (CETP) gene influences lipid responses to the consumption of kiwifruit in hypercholesterolaemic men. *Br J Nutr*. 2014;111(6):1077–84. <https://doi.org/10.1017/s0007114513003437>.
 63. Papp AC, Pinsonneault JK, Wang D, Newman LC, Gong Y, Johnson JA, et al. Cholesteryl ester transfer protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. *PLoS one*. 2012;7(3):e31930–e31930. <https://doi.org/10.1371/journal.pone.0031930>.
 64. National Library of Medicine. Reference SNP (rs) Report. 2021. https://www.ncbi.nlm.nih.gov/snp/rs5882?vertical_tab=true#frequency_tab 18 June 2021.
 65. Hosseini-Esfahani F, Esfandiari Z, Mirmiran P, Daneshpour MS, Ghanbarian A, Azizi F. The interaction of cholesteryl ester transfer protein gene variations and diet on changes in serum lipid profiles. *Eur J Clin Nutr*. 2019;73(9):1291–8. <https://doi.org/10.1038/s41430-019-0397-x>.

66. Esfandiari Z, Hosseini-Esfahani F, Daneshpour MS, Zand H, Mirmiran P, Azizi F. Cholesteryl ester transfer protein gene variations and macronutrient interaction in relation to metabolic syndrome: Tehran lipid and glucose study. *Iran J Basic Med Sci.* 2018;21(6):586–592. <https://doi.org/10.22038/ijbms.2018.26768.6555>
67. Chang CK, Snook JT. The cholesterolaemic effects of dietary fats in cholesteryl ester transfer protein transgenic mice. *Br J Nutr.* 2001;85(6):643–8. <https://doi.org/10.1079/bjn2001320>.
68. Cheema SK, Agarwal-Mawal A, Murray CM, Tucker S. Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet. *J Lipid Res.* 2005;46(11):2356–66. <https://doi.org/10.1194/jlr.M500051-JLR200>.
69. Qian F, Korat AA, Malik V, Hu FB. Metabolic effects of mono-unsaturated fatty acid-enriched diets compared with carbohydrate or polyunsaturated fatty acid-enriched diets in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Care.* 2016;39(8):1448. <https://doi.org/10.2337/dc16-0513>.
70. Gudnason V, Thormar K, Humphries SE. Interaction of the cholesteryl ester transfer protein I405V polymorphism with alcohol consumption in smoking and non-smoking healthy men, and the effect on plasma HDL cholesterol and apoAI concentration. *Clin Genet.* 1997;51(1):15–21. <https://doi.org/10.1111/j.1399-0004.1997.tb02407.x>.
71. Rudkowska I, Ouellette C, Dewailly E, Hegele RA, Boiteau V, Dubé-Linteau A, et al. Omega-3 fatty acids, polymorphisms and lipid related cardiovascular disease risk factors in the Inuit population. *Nutr Metab (Lond).* 2013;10(1):26. <https://doi.org/10.1186/1743-7075-10-26>.
72. Fernandez ML, West KL. Mechanisms by which dietary fatty acids modulate plasma lipids. *J Nutr.* 2005;135(9):2075–8. <https://doi.org/10.1093/jn/135.9.2075>.
73. Raposo HF, Patrício PR, Simões MC, Oliveira HCF. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene. *J Nutr Biochem.* 2014;25(6):669–74. <https://doi.org/10.1016/j.jnutbio.2014.02.008>.
74. Terán-García M, Després JP, Tremblay A, Bouchard C. Effects of cholesterol ester transfer protein (CETP) gene on adiposity in response to long-term overfeeding. *Atherosclerosis.* 2008;196(1):455–60. <https://doi.org/10.1016/j.atherosclerosis.2006.12.005>.
75. Bustami J, Sukiasyan A, Kupcinskas J, Skieceviciene J, Iakoubov L, Szwed M, et al. Cholesteryl ester transfer protein (CETP) I405V polymorphism and cardiovascular disease in eastern European Caucasians – a cross-sectional study. *BMC Geriatr.* 2016;16(1):144. <https://doi.org/10.1186/s12877-016-0318-y>.
76. Walia GK, Gupta V, Aggarwal A, Asghar M, Dudbridge F, Timpson N, et al. Association of common genetic variants with lipid traits in the Indian population. *PLoS ONE.* 2014;9(7):e101688. <https://doi.org/10.1371/journal.pone.0101688>.
77. Zhu L, Luu T, Emfinger CH, Parks BA, Shi J, Trefts E, et al. CETP inhibition improves HDL function but leads to fatty liver and insulin resistance in CETP-expressing transgenic mice on a high-fat diet. *Diabetes.* 2018;67(12):2494–506. <https://doi.org/10.2337/db18-0474>.
78. McCaffery JM, Ordovas JM, Huggins GS, Lai CQ, Espeland MA, Tate DF, et al. Weight gain prevention buffers the impact of CETP rs3764261 on high density lipoprotein cholesterol in young adulthood: the Study of Novel Approaches to Weight Gain Prevention (SNAP). *Nutr Metab Cardiovasc Dis.* 2018;28(8):816–21. <https://doi.org/10.1016/j.numecd.2018.02.018>.
79. Alsulami S, Nyakotey DA, Dudek K, Bawah AM, Lovegrove JA, Annan RA, et al. Interaction between metabolic genetic risk score and dietary fatty acid intake on central obesity in a Ghanaian population. *Nutrients.* 2020;12(7). <https://doi.org/10.3390/nu12071906>
80. Srisawasdi P, Rodcharoen P, Vanavanan S, Chittamma A, Sukasem C, Na Nakorn C, et al. Association of CETP gene variants with atherogenic dyslipidemia among Thai patients treated with statin. *Pharmgenomics Pers Med.* 2021;14:1–13. <https://doi.org/10.2147/pgpm.S278671>.
81. Hsu TW, Tantoh DM, Lee KJ, Ndi ON, Lin LY, Chou MC, et al. Genetic and non-genetic factor-adjusted association between coffee drinking and high-density lipoprotein cholesterol in Taiwanese adults: stratification by sex. *Nutrients.* 2019;11(5). <https://doi.org/10.3390/nu11051102>
82. Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, Ruidavets JB, et al. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. *Genet Epidemiol.* 2000;19(1):64–80. [https://doi.org/10.1002/1098-2272\(200007\)19:1%3c64::Aid-gepi5%3e3.0.Co;2-e](https://doi.org/10.1002/1098-2272(200007)19:1%3c64::Aid-gepi5%3e3.0.Co;2-e).
83. Walker CG, Loos RJJ, Olson AD, Frost GS, Griffin BA, Lovegrove JA, et al. Genetic predisposition influences plasma lipids of participants on habitual diet, but not the response to reductions in dietary intake of saturated fatty acids. *Atherosclerosis.* 2011;215(2):421–7. <https://doi.org/10.1016/j.atherosclerosis.2010.12.039>.
84. Rudkowska I, Guénard F, Julien P, Couture P, Lemieux S, Barbier O, et al. Genome-wide association study of the plasma triglyceride response to an n-3 polyunsaturated fatty acid supplementation. *J Lipid Res.* 2014;55(7):1245–53. <https://doi.org/10.1194/jlr.M045898>.
85. Bodhini D, Gaal S, Shatwan I, Ramya K, Ellahi B, Surendran S, et al. Interaction between TCF7L2 polymorphism and dietary fat intake on high density lipoprotein cholesterol. *PLoS ONE.* 2017;12(11):e0188382–e0188382. <https://doi.org/10.1371/journal.pone.0188382>.
86. Galan-Chilet I, Guallar E, Martin-Escudero JC, De Marco G, Dominguez-Lucas A, Gonzalez-Manzano I, et al. Do genes modify the association of selenium and lipid levels? *Antioxid Redox Signal.* 2015;22(15):1352–62. <https://doi.org/10.1089/ars.2015.6248>.
87. Hasani M, Djalalinia S, Sharifi F, Varmaghani M, Zarei M, Abdar ME, et al. Effect of selenium supplementation on lipid profile: a systematic review and meta-analysis. *Horm Metab Res.* 2018;50(10):715–27. <https://doi.org/10.1055/a-0749-6655>.
88. Mirmiran P, Esfandiari Z, Hosseini-Esfahani F, Koochakpoor G, Daneshpour MS, Sedaghati-Khayat B, et al. Genetic variations of cholesteryl ester transfer protein and diet interactions in relation to lipid profiles and coronary heart disease: a systematic review. *Nutr Metab (Lond).* 2017;14:77. <https://doi.org/10.1186/s12986-017-0231-1>.
89. Tekola-Ayele F, Doumatey AP, Shriner D, Bentley AR, Chen G, Zhou J, et al. Genome-wide association study identifies African-ancestry specific variants for metabolic syndrome. *Mol Genet Metab.* 2015;116(4):305–13. <https://doi.org/10.1016/j.ymgme.2015.10.008>.
90. Graff M, Emery LS, Justice AE, Parra E, Below JE, Palmer ND, et al. Genetic architecture of lipid traits in the Hispanic community health study/study of Latinos. *Lipids Health Dis.* 2017;16(1):200. <https://doi.org/10.1186/s12944-017-0591-6>.
91. Hebbbar P, Nizam R, Melhem M, Alkayal F, Elkum N, John SE, et al. Genome-wide association study identifies novel recessive genetic variants for high TGs in an Arab population. *J Lipid Res.* 2018;59(10):1951–66. <https://doi.org/10.1194/jlr.P080218>.
92. Chasman DI, Paré G, Zee RY, Parker AN, Cook NR, Buring JE, et al. Genetic loci associated with plasma concentration of

- low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. *Circ Cardiovasc Genet.* 2008;1(1):21–30. <https://doi.org/10.1161/circgenetics.108.773168>.
93. Keller M, Schleinitz D, Förster J, Tönjes A, Böttcher Y, Fischer-Rosinsky A, et al. THOC5: a novel gene involved in HDL-cholesterol metabolism. *J Lipid Res.* 2013;54(11):3170–6. <https://doi.org/10.1194/jlr.M039420>.
 94. Dumitrescu L, Brown-Gentry K, Goodloe R, Glenn K, Yang W, Kornegay N, et al. Evidence for age as a modifier of genetic associations for lipid levels. *Ann Hum Genet.* 2011;75(5):589–97. <https://doi.org/10.1111/j.1469-1809.2011.00664.x>.
 95. Hoffmann TJ, Theusch E, Haldar T, Ranatunga DK, Jorgenson E, Medina MW, et al. A large electronic-health-record-based genome-wide study of serum lipids. *Nat Genet.* 2018;50:401+. <https://doi.org/10.1038/s41431-018-0001-1>.
 96. Sandhu MS, Waterworth DM, Debenham SL, Wheeler E, Papadakis K, Zhao JH, et al. LDL-cholesterol concentrations: a genome-wide association study. *Lancet.* 2008;371(9611):483–91. [https://doi.org/10.1016/S0140-6736\(08\)60208-1](https://doi.org/10.1016/S0140-6736(08)60208-1).
 97. Surakka I, Whitfield JB, Perola M, Visscher PM, Montgomery GW, Falchi M, et al. A genome-wide association study of monozygotic twin-pairs suggests a locus related to variability of serum high-density lipoprotein cholesterol. *Twin Res Hum Genet.* 2012;15(6):691–9. <https://doi.org/10.1017/thg.2012.63>.
 98. Nettleton JA, Steffen LM, Ballantyne CM, Boerwinkle E, Folsom AR. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. *Atherosclerosis.* 2007;194(2):e131-140. <https://doi.org/10.1016/j.atherosclerosis.2006.11.025>.
 99. Kim DS, Burt AA, Ranchalis JE, Jarvik ER, Rosenthal EA, Hatsukami TS, et al. Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. *J Lipid Res.* 2013;54(5):1512–20. <https://doi.org/10.1194/jlr.P035238>.
 100. Marques-Vidal P, Bochud M, Paccaud F, Waterworth D, Bergmann S, Preisig M, et al. No interaction between alcohol consumption and HDL-related genes on HDL cholesterol levels. *Atherosclerosis.* 2010;211(2):551–7. <https://doi.org/10.1016/j.atherosclerosis.2010.04.001>.
 101. Lin E, Kuo PH, Liu YL, Yang AC, Kao CF, Tsai SJ. Association and interaction of APOA5, BUD13, CETP, LIPA and health-related behavior with metabolic syndrome in a Taiwanese population. *Sci Rep.* 2016;6:36830. <https://doi.org/10.1038/srep36830>.
 102. Rezazadeh K, Rezazadeh F, Ebrahimi-Mameghani M. The effect of artichoke leaf extract supplementation on lipid and CETP response in metabolic syndrome with respect to Taq 1B CETP polymorphism: a randomized placebo-controlled clinical trial. *Eur J Integr Med.* 2018;17:112–8. <https://doi.org/10.1016/j.eujim.2017.12.008>.
 103. Lottenberg AM, Nunes VS, Nakandakare ER, Neves M, Bernik M, Lagrost L, et al. The human cholesteryl ester transfer protein I405V polymorphism is associated with plasma cholesterol concentration and its reduction by dietary phytosterol esters. *J Nutr.* 2003;133(6):1800–5. <https://doi.org/10.1093/jn/133.6.1800>.
 104. Aitken WAE, Chisholm AWAH, Duncan AW, Harper MJ, Humphries SE, Mann JI, et al. Variation in the cholesteryl ester transfer protein (CETP) gene does not influence individual plasma cholesterol response to changes in the nature of dietary fat. *Nutr Metab Cardiovasc Dis.* 2006;16(5):353–63. <https://doi.org/10.1016/j.numecd.2005.06.007>.
 105. Hall WL, Vafeiadou K, Hallund J, Bugel S, Reimann M, Koebnick C, et al. Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. *Am J Clin Nutr.* 2006;83(3):592–600. <https://doi.org/10.1093/ajcn.83.3.592>.
 106. Plat J, Mensink RP. Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption. *Eur J Clin Invest.* 2002;32(4):242–50. <https://doi.org/10.1046/j.1365-2362.2002.00982.x>.
 107. Wallace AJ, Mann JI, Sutherland WH, Williams S, Chisholm A, Skeaff CM, et al. Variants in the cholesterol ester transfer protein and lipoprotein lipase genes are predictors of plasma cholesterol response to dietary change. *Atherosclerosis.* 2000;152(2):327–36. [https://doi.org/10.1016/s0021-9150\(99\)00490-6](https://doi.org/10.1016/s0021-9150(99)00490-6).
 108. Wallace AJ, Humphries SE, Fisher RM, Mann JI, Chisholm A, Sutherland WH. Genetic factors associated with response of LDL subfractions to change in the nature of dietary fat. *Atherosclerosis.* 2000;149(2):387–94. [https://doi.org/10.1016/s0021-9150\(99\)00328-7](https://doi.org/10.1016/s0021-9150(99)00328-7).
 109. MacKay DS, Eck PK, Gebauer SK, Baer DJ, Jones PJ. CYP7A1-rs3808607 and APOE isoform associate with LDL cholesterol lowering after plant sterol consumption in a randomized clinical trial. *Am J Clin Nutr.* 2015;102(4):951–7. <https://doi.org/10.3945/ajcn.115.109231>.
 110. Darabi M, Abolfathi AA, Noori M, Kazemi A, Ostadrahimi A, Rahimpour A, et al. Cholesteryl ester transfer protein I405V polymorphism influences apolipoprotein A-I response to a change in dietary fatty acid composition. *Horm Metab Res.* 2009;41(7):554–8. <https://doi.org/10.1055/s-0029-1192034>.
 111. Friedlander Y, Leitersdorf E, Vecsler R, Funke H, Kark J. The contribution of candidate genes to the response of plasma lipids and lipoproteins to dietary challenge. *Atherosclerosis.* 2000;152(1):239–48. [https://doi.org/10.1016/S0021-9150\(99\)00474-8](https://doi.org/10.1016/S0021-9150(99)00474-8).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.